Okyo Pharma receives $1.4M in non-dilutive financing

OKYO Pharma (OKYO) has received $1.4M in non-dilutive funding. The company said, “This significant financial funding strengthens the Company’s ability to advance its innovative pipeline without diluting shareholder value. The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.”